Advertisement
Advertisement
RNA
Atrium Therapeutics, Inc. Common Stock
13.00
USDSponsored
-0.36
-2.69%
May 29, 15:59 UTC -4
Closed
After-Market
12.99
-0.01
-0.04%
RNA Earnings Reports
Positive Surprise Ratio
RNA beat 13 of 23 last estimates.
57%
Next Report
Date of Next Report
Aug 05, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.80M
/-$1.32
Implied change from Q1 26 (Revenue/ EPS)
-85.73%
/+36.08%
Implied change from Q2 25 (Revenue/ EPS)
-27.16%
/+9.09%
Atrium Therapeutics, Inc. Common Stock earnings per share and revenue
On May 14, 2026, RNA reported earnings of -0.97 USD per share (EPS) for Q1 26, beating the estimate of -1.06 USD, resulting in a 8.53% surprise. Revenue reached 19.64 million, compared to an expected 2.02 million, with a 872.03% difference. The market reacted with a -0.30% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 9 analysts forecast an EPS of -1.32 USD, with revenue projected to reach 2.80 million USD, implying an increase of 36.08% EPS, and decrease of -85.73% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Compugen Ltd
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-8.11%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
OS Therapies Incorporated
Report Date
May 18, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.27
Surprise
-49.83%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Atrium Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Atrium Therapeutics, Inc. Common Stock reported EPS of -$0.97, beating estimates by 8.53%, and revenue of $19.64M, 872.03% above expectations.
How did the market react to Atrium Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -0.3%, changed from $13.27 before the earnings release to $13.23 the day after.
When is Atrium Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 05, 2026.
What are the forecasts for Atrium Therapeutics, Inc. Common Stock's next earnings report?
Based on 9
analysts, Atrium Therapeutics, Inc. Common Stock is expected to report EPS of -$1.32 and revenue of $2.80M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement